



Dedicated to treating rare diseases

March 23, 2020

The evolution of the situation surrounding COVID-19 continues and brings Medunik USA, like many companies, to implement a contingency plan in order to ensure the continuity of its operations along with the safety of its employees. We remain on the lookout for recommendations and preventive measures by the various levels of government, and adjust our own measures daily.

First, Medunik USA does not anticipate any interruption in the production and distribution of its products. Our stocks of products, as well as our distribution strategies, ensure that we are able to meet the needs of patients for the foreseeable future.

As the safety of our employees is a priority, we have implemented measures so that several of them can work remotely in the coming weeks. The objective of this measure is to limit the number of employees in the office as a precaution, to prevent the spread of the virus and to ensure the safety of employees who provide essential services. Different technological means will be made available to them to maintain communications and current operations. You can therefore count on the same level of service as in normal times.

Although the situation remains constantly evolving, we are actively examining the possibilities to ensure that we are prepared if the situation continues to worsen.

If you have specific questions regarding one of our products or suspect you have had a reaction to one of them, our [Medical Information Service](#) remains open for you. You can also contact FDA at 1-800-FDA-1088 or <http://www.fda.gov/medwatch> to report a suspected adverse reaction.

Best regards,

Tanya Carro
General Manager